SUBOXONE, (buprenorphine/naloxone), treatment of opioid dependence.

Opinions on drugs - Posted on Sep 10 2015

Reason for request

Renewal of inclusion

No clinical benefit demonstrated in substitution treatment for IV opiate dependence


  • SUBOXONE, a combination of high-dose buprenorphine (HDB) and naloxone, has Marketing Authorisation in the substitution treatment of opioid drug dependence, within the framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse.
  • Treatment is intended for use only in adults and adolescents over 15 years of age who have agreed to be treated for addiction.
  • This is an additional therapeutic tool, used mainly on the first prescription of HDB in intravenous drug addicts who have been informed of the special features and limitations of the medicinal product and who wish to have a medicinal aid of this kind.

Clinical Benefit



Clinical Added Value

no clinical added value


Therapeutic use



Contact Us

Évaluation des médicaments